＜＜Back

Next＞＞

Vol. 29　Suppl. 2　2001

Opening Remarks

H. Kawasaki

Jpn Pharmacol Ther 2001 29(s2) s143

---

Growth inhibition and induction of differentiation through PPARγ activation in immortalized human hepatocytes

S. Shishido et al.

Jpn Pharmacol Ther 2001 29(s2) s149-54

---

Increased expressions of p21^WAF1/Cip1, p27^Kip1, and p18^INK4c through PPAR－γ activation lead to G1 arrest of the cell－cycle in human hepatoma cells

H. Koga et al.

Jpn Pharmacol Ther 2001 29(s2) s155-9

---

The effects of endothelin－1 on cell proliferation, apoptosis, collagen metabolism in hepatic stellate cells

M. Koda et al.

Jpn Pharmacol Ther 2001 29(s2) s161-5

---

A novel inhibitory mechanism of platelet－derived growth factor－dependent signaling by N－acetylcysteine in hepatic stellate cell

H. Okuyama et al.

Jpn Pharmacol Ther 2001 29(s2) s167-70

---

The role of angiotensin－II on liver fibrosis development and its regulation

H. Yoshiji et al.

Jpn Pharmacol Ther 2001 29(s2) s171-5

---

【Discussion 1～5】　

Jpn Pharmacol Ther 2001 29(s2) s177-80

---

Protective effects of ulinastatin on endotoxin induced liver damage and downregulation of nitric oxide in hepatocytes during endotoxemia

T. Kono et al.

Jpn Pharmacol Ther 2001 29(s2) s181-4

---

Effects of glycyrrhizin on the rat hepatocytes via the heat shock protein 90 expression

T. Yoh et al.　

Jpn Pharmacol Ther 2001 29(s2) s185-7

---

A role of endogenous thyrotropin－releasing hormone of the brain in hepatic blood flow

M. Yoneda et al.

Jpn Pharmacol Ther 2001 29(s2) s189-92

---

Acetaminophen and diethylmaleate sensitize mouse hepatocytes to tumor necrosis factor－α induced apoptosis

H. Nagai et al.

Jpn Pharmacol Ther 2001 29(s2) s193-200

---

【Discussion 6～9】

Jpn Pharmacol Ther 2001 29(s2) s201-3

---

Dynamics of serum thioredoxin levels as an indicator of oxidative stress in patients with chronic hepatitis C

Y. Sumida et al.

Jpn Pharmacol Ther 2001 29(s2) s205-8

---

Effect of lactoferrin in chronic hepatitis C patients

M. Iwasa et al.

Jpn Pharmacol Ther 2001 29(s2) s209-10

---

Clinical study on the usefulness of hepatic venous blood sampling for evaluating residual hepatic reserves in patients with liver diseases－Focusing on MEGX ratio－

K. Matsuyama et al.

Jpn Pharmacol Ther 2001 29(s2) s211-3

---

A study of nitric oxide levels in portal hypertensive disease accompanied with solitary gastric varices

H. Hidaka et al.

Jpn Pharmacol Ther 2001 29(s2) s215-7

---

Enhanced expression of endothelin B receptor in human cirrhotic liver

H. Yokomori et al.

Jpn Pharmacol Ther 2001 29(s2) s219-22

---

【Discussion 10～14】

Jpn Pharmacol Ther 2001 29(s2) s223-5

---

The plasma disappearance rate of indocyanine green in a turbid media using Monte Carlo simulation and diffusion approximation

K. Awazu et al.

Jpn Pharmacol Ther 2001 29(s2) s227-32

---

Changes in biliary taurolithocholate－3－sulfate and temocaprilat excretion in cholestatic rate induced by ethinylestradiol and bile duct－ligation

M. Ohashi et al.

Jpn Pharmacol Ther 2001 29(s2) s233-5

---

Establishment of MDCK cells co－exprssing human OATP2 and MRP2

M. Sasaki et al.

Jpn Pharmacol Ther 2001 29(s2) s237-8

---

Effects of diosgenin on the bile flow and canalicular membrane
－Fluidity and canalicurar membrane protein in rats－

A. Yamaguchi et al.

Jpn Pharmacol Ther 2001 29(s2) s239-40

---

Hydrophilic bile salts cytoprotective function against cyclosporin A caused cholestasis through enhancing canalicular membrane fluidity and transporter activity

K. Tsuboi et al.

Jpn Pharmacol Ther 2001 29(s2) s241-2

---

Drug－drug interaction at the biliary excretion process
－Prediction of the potential cholestatic activity using bile canalicular membrane vesicles－

M. Horikawa et al.

Jpn Pharmacol Ther 2001 29(s2) s243-5

---

Change in hepatotropic substances after PTPO & BRTO

H. Takahashi et al.

Jpn Pharmacol Ther 2001 29(s2) s247-9

---

【Discussion 15～21】

Jpn Pharmacol Ther 2001 29(s2) s251

---

The transition and future view of the Japanese study group for the pathophysiology of the liver

H. Kawasaki

Jpn Pharmacol Ther 2001 29(s2) s255

---

Discussion

Jpn Pharmacol Ther 2001 29(s2) s263

---

Closing Remarks

H. Fukui

Jpn Pharmacol Ther 2001 29(s2) s265